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Liver transplantation is the only cure for endstage liver disease and is an increasingly utilized treatment for hepatocellular carcinoma (HCC) in select populations. Despite improved survival with transplantation, recipients are at risk for a host of metabolic phenomena post-transplant due to transplant medications, resumption of previous dietary habits, and their underlying disease processes. New-onset diabetes after transplantation (NODAT) is particularly common, with a reported incidence of 10.8-61% (1) (2) (3) (4) , and is linked to increased cardiovascular events, mortality, and other complications (2, 5, 6) .
Accurately predicting which patients will develop NODAT could lead to interventions to ameliorate these complications. Established risk factors for NODAT include prolonged prednisone use, tacrolimus immunosuppression, HCC, and hepatitis C (HCV) (1, 7) . It is known that body composition -specifically body mass index (BMI), waist circumference, and waist to hip ratio (i.e., "pear-shape") -is correlated with the development of diabetes in non-cirrhotic populations. However, these measurements are difficult to apply in pretransplant patients who have varying degrees of ascites, subcutaneous edema, and sarcopenia that make these measurements inaccurate.
The emerging field of analytic morphomics has enabled us to make more precise measurements of body composition using computed tomography (CT) scans. It has been shown that morphomic measures of fat distribution and quantification of trunk musculature using CT scans can help quantify surgical risk in a variety of populations, including liver transplant recipients (8) (9) (10) (11) (12) . In addition, it has been shown that visceral adiposity and relative skeletal muscle mass in non-transplant patients are associated with the development of insulin resistance (13, 14) . To our knowledge, there have been no studies investigating the utility of these measures in predicting NODAT in liver transplant recipients.
We therefore aimed to determine whether analytic morphomics could be used to predict the incidence of NODAT in patients undergoing liver transplantation. We hypothesized that higher fat and lower trunk muscle size would be associated with NODAT.
Methods

Study population
This study was approved by the University of Michigan Institutional Review Board. This was a retrospective study of adult patients who underwent liver transplantation at a single large academic hospital between 2000 and 2011 with available peri-operative CT imaging. Eligible scans were those within 90 d of the operation that included the L4 vertebral level. We further narrowed this group to include only those patients without documented diabetes at the time of transplantation. Lastly, we excluded patients who died within the first 10 months post-transplant. This subset served as our study cohort (Fig. 1) . The following demographic and clinical characteristics were collected retrospectively from the electronic medical records: recipient age, gender, race, height, weight, BMI, serum albumin, model for end-stage liver disease score, liver disease etiology (or etiologies if multiple; see Table S1 for descriptions), tobacco use, diabetes family history, hyperlipidemia diagnosis, and immunosuppressive regimen active at 10 months post-transplant (tacrolimus, cyclosporine, and prednisone). Chart review was performed using the electronic medical record search engine (EMERSE) to query clinical documentation of these characteristics (15) . At conclusion of this step, 10% of charts were manually reviewed by a single physician reviewer for quality assurance. Fig. 2 shows the morphomic measures considered in this analysis: total psoas area, visceral fat area, subcutaneous fat area, and anterior subcutaneous fat thickness. We also considered the following ratios: visceral fat to subcutaneous fat areas, visceral fat to total psoas areas, and subcutaneous fat to total psoas areas. CT scans were processed using semi-automated methods programmed into MAT- The fascia is outlined, and within this region, the visceral fat is portrayed by a heat map of density. The skin and the psoas muscles are outlined as well.
Analytic morphomics
LAB v. 2013a (MathWorks, Natick, MA, USA) after de-identified DICOM files were loaded in the morphomics server. The methods for measuring total psoas area are well described elsewhere (8, 9) . Initially, each scan was anatomically indexed in a semi-automated fashion so that precise measurements could be made referenced to vertebral level (16) . The cross-sectional areas of the left and right psoas muscles were computed inferior to the L4 vertebral level. These areas were summed to compute total psoas area, and this measurement was adjusted for the average Hounsfield units (density) of the psoas muscle to account for fatty infiltration (9) . The resulting measure is termed lean psoas area.
Fat areas were measured at L4 as well for consistency. The fascial and skin envelopes were identified automatically after user-defined identification of several pelvic points and the linea alba. This was followed by user verification and editing as needed. Within the fascial envelope, the Hounsfield units of each pixel were calculated, and any pixels that fell within the density range of fat were deemed visceral fat. Between the skin and fascia contours, Hounsfield units were again used to identify subcutaneous fat. Because many larger patients have lateral regions of their subcutaneous fat cropped out of the CT images, we also included anterior subcutaneous fat thickness as a measure, which was available on all patients. This measure was computed as the shortest distance between the fascia and skin contours at the linea alba. Because a linear distance measure is more subject to random variation than area measurements, this measure was averaged across the T12 to L4 vertebral levels (17) .
Outcome
The primary outcome of interest was combined NODAT -defined as incidence of NODAT at or beyond 10 months post-transplant. Because our follow-up began at 10 months post-transplant, we censored out patients who died prior to this 10-month mark. Ten months has been used as the threshold in prior studies, as by this time, most patients are clinically stable, have been taken off steroids, and are therefore more likely to have stable blood sugars. This allows us to avoid misclassifying transient diabetes as NO-DAT (1). Other studies have used six or 12 months as thresholds; however, differences in incidence between the two periods were similar, and therefore, the exact time point is likely not significant (4, 6) . For descriptive purposes, we also subdivided NODAT into "earlier-onset" (NODAT incident prior to and persistent through the 10-month time point) and "lateronset" (NODAT incident beyond 10 months). We used EMERSE to retrospectively review the electronic medical records for mention of the following terms: NODAT, diabetes, DM, hyperglycemia, and insulin. For patients identified in this manner, we verified true diagnosis of NODAT according to the following American Diabetes Association criteria: A1C ≥ 6.5, fasting plasma glucose ≥ 126, oral glucose tolerance test at two h ≥ 200, random glucose ≥ 200, or any insulin use.
Statistical analysis
Descriptive statistics were computed for the study cohort. Categorical variables were summarized by frequency tables and compared using a chi-square test or Fisher's exact test, as appropriate. Continuous variables were summarized by mean and standard deviation and compared using a Student's t-test or a Wilcoxon rank-sum test, as appropriate. For regression analysis, morphomic variables were standardized by gender to facilitate interpretation of the regression coefficients, and the outcome was combined NODAT incidence (therefore including earlier-onset and later-onset). Logistic regression was used to identify factors associated with NO-DAT incidence on bivariate analysis. Variables with a p-value ≤ 0.20 were considered "candidate predictors." Multivariate logistic regression was then applied to identify factors independently associated with NODAT incidence. All candidate predictors and clinically relevant variables were entered into the logistic regression analysis, and backward stepwise selection was used to determine a subset of adjustment covariates. Predictive ability of the models was assessed using the area under the receiver operating characteristic (C-statistic). Model goodness of fit was verified using the Hosmer-Lemeshow test. All statistical analysis was performed using STATA v. 13 (College Station, TX, USA).
Results
Two hundred and sixteen patients met our inclusion criteria. Table 1 displays the demographic and clinical characteristics of this cohort. The most common underlying reasons for liver transplantation were HCV (37.5%), alcoholic cirrhosis (26.9%), HCC (26.4%), and cholestatic disease (19.9%). The majority of patients (79.6%) were on tacrolimus, and 42.1% of patients were on prednisone at 10 months post-transplant. The overall incidence of NODAT was 28.2% (61 patients). Of these patients, 77.1% (47 patients) had earlieronset NODAT (present at 10 months post-transplant) and 23.0% (14 patients) had later-onset NODAT (incident beyond 10 months post-transplant). Of this latter group, the median time from transplant to diagnosis of NODAT was 26 months. Table 2 displays the estimated (unadjusted) parameters for morphomic variables from the logistic regression analyses of the primary outcome (combined NODAT). In bivariate analysis, anterior subcutaneous fat thickness was the only significant morphomic predictor of NODAT (odds ratio [OR] = 1.43 per standard deviation increase, 95% CI 1.07-1.92, p = 0.02). Other variables significantly associated with NODAT incidence in bivariate analysis included tobacco use in the past year (p = 0.03), HCV (p = 0.005), and cholestatic disease (which was protective; p = 0.004). The overall distribution for anterior subcutaneous fat thickness was skewed right, and values ranged from 2.3 to 50.9 mm. There was a strong positive correlation between anterior subcutaneous fat thickness and subcutaneous fat area (r = 0.80).
In multivariate analysis, subcutaneous fat thickness remained significantly associated with NODAT (OR = 1.43, 95% CI 1.00-1.88, p = 0.047), along with HCV, and "other" diagnosis (see Table S1 for description of "other" diagnosis). BMI was not significantly different. Cholestatic disease was removed from multivariate analysis because it was mutually exclusive with HCV and therefore predicted each other in modeling. The Cstatistic for this model was 0.70. The covariates in this model were then used to calculate adjusted rates of NODAT incidence. Fig. 3 shows these rates by gender-stratified tertile of anterior subcutaneous fat thickness. Patients with the most anterior subcutaneous fat had 1.7-fold higher incidence of NODAT compared to patients with the least anterior subcutaneous fat.
For our secondary analysis, we divided patients into earlier-onset and later-onset NODAT. Table 3 shows the median morphomic values for the following three groups of patients: those without NO-DAT, those with earlier-onset NODAT, and those with later-onset NODAT. Compared to patients without NODAT, visceral fat area and the ratio of visceral fat to lean psoas area were significantly larger in the later-onset NODAT group (visceral fat area: p = 0.02; ratio: p = 0.01). Compared to patients without NODAT, anterior subcutaneous fat thickness was significantly larger in both the earlier-onset group (p = 0.04) and the later-onset group (p = 0.02).
As a sensitivity analysis, we compared the morphomic characteristics of patients with diabetes at the time of transplant (excluded initially from our main cohort) and patients in our cohort who developed NODAT (Table S2 ). Compared to diabetic liver transplant candidates, the onset NODAT patients had significantly lower visceral fat (p = 0.002), larger lean psoas area (p = 0.02), and smaller ratios of subcutaneous fat to leas psoas area (p = 0.001) and smaller visceral fat to lean psoas area (p < 0.001). The later-onset NODAT patients were similar to the diabetic comparison group in all morphomic aspects. The patients in our study cohort who did not develop NODAT were significantly different from the diabetic comparison group in all morphomic aspects (lower fat and larger muscles in the patients without NO-DAT) except the ratio of visceral to subcutaneous fat.
Tacrolimus use was not found to be significant in bivariate or multivariate modeling. As a sensitivity analysis, we ran the models again using average tacrolimus trough levels from date of transplant to six months post-transplant (data available for all but six patients). By itself, average tacrolimus trough was a significant predictor of NODAT, but this measure was not significant when adjusting for subcutaneous fat thickness or when included in the multivariate model.
Discussion
This is the first study evaluating analytic morphomics in a liver transplant population to determine associations with NODAT. We found that subcutaneous fat thickness was independently associated with NODAT, even after adjustment for other clinical and demographic characteristics. In addition, visceral fat area and the ratio of visceral fat to lean psoas were associated with later-onset (beyond 10 months) NODAT. The incidence of NODAT in our study was 28.2% -well within typical values found in other studies (1) (2) (3) (4) . Similar to other studies, the variables we found to be associated with Fig. 3 . Adjusted incidence of combined new-onset diabetes after transplantation (NODAT) by tertile of subcutaneous fat thickness. After adjustment for hepatitis C, hyperlipidemia, and "other" diagnoses, patients with the most anterior subcutaneous fat had a 1.7-fold higher incidence of NODAT compared to the patients with the least anterior subcutaneous fat (36% compared with 21%). Combined NODAT includes both earlier-and later-onset NODAT. NODAT included tobacco use and HCV, with cholestatic disease being protective from NODAT. However, not all previously proven risk factors (e.g., HCC and tacrolimus use) were found to be statistically significant, likely due to the small sample size and to the relatively large percentage of patients on tacrolimus rather than cyclosporine or other agents.
As with all retrospective studies, we were limited by the data collection available in the chart, and it is possible that not all patients had adequate testing for NODAT or that risk factors were not mentioned within the chart. We attempted to mitigate this factor by searching broadly for multiple search terms and including both chart review and laboratory data in determining NODAT status. In addition, this study is susceptible to selection bias, as only those patients who had CT scans and who maintained follow-up could be included. We were not able to measure all factors associated with NODAT as caloric intake and exercise are difficult to measure retrospectively. Although we attempted to correct for any measured confounders using logistic regression, retrospective studies are prone to these types of biases and do not prove causality. A larger prospective study would need to be undertaken to verify our findings. Concerning our definition of NODAT, there is no clear consensus on a temporal definition; we chose presence at 10 months post-transplant as our threshold. We also ran the analyses using survival analysis techniques (time until NO-DAT onset) and we observed the same findings, with subcutaneous fat thickness as the only significant morphomic predictor (data not shown). Finally, this is a single-center study, and therefore, results from our population may not be generalizable to other centers.
Other studies have shown visceral fat at the L4 umbilicus and visceral to subcutaneous fat ratio to be related to surgical risk and diabetes; however, we did not find these measurements to be significant in our cohort (12, 13) . In our sample, we found that subcutaneous fat could not be adequately measured in 12% of patients due to cropping of CT scan images on the lateral aspects of the field, presumably underestimating subcutaneous fat for these patients. By using midline subcutaneous fat, which is correlated with total subcutaneous fat, this limitation was eliminated leaving us with an easy-to-measure variable that is correlated with NODAT. Midline subcutaneous fat could also reflect a different body shape or fat distribution that predisposes to diabetes. Alternatively, fat thickness may be less confounded by body size, making it a more reliable measure of fat. We did observe significantly higher visceral fat in the later-onset NODAT patients and more similarities between the morphomics of lateronset patients and patients who had diabetes pretransplant. This could possibly point to a biochemical difference between earlier-and lateronset diabetes. Patients who develop later-onset NODAT may be genetically or physically pre-disposed to diabetes (i.e., they would have developed diabetes eventually without a transplant). Those with earlier-onset NODAT may instead have developed diabetes due to immunosuppression or other transplant-related factors. Due to small sample size, we were unable to consider timing of NODAT incidence in our primary multivariate analysis. This finding merits further study as this would help to reveal a population at risk for NODAT that might not be normally considered at risk.
Given the high morbidity associated with NO-DAT, it is imperative that high-risk patients are identified early so that modifiable risk factors can be addressed and corrected. The 2003 International Consensus Guidelines recommend evaluating and identifying patients at risk for NODAT during the initial consult for transplantation (18) . Pre-transplant patients often undergo pre-operative crosssectional imaging in the course of their work-up and for HCC screening. By using these already available imaging scans, we can further identify atrisk patients who would merit individualized weight, diet, and exercise counseling, which has been shown to prevent diabetes in high-risk patients (19) . Additional interventions could target immunosuppressive therapy by focusing on minimizing steroids (18) . In conclusion, our study shows that analytic morphomics may be useful for assessing NODAT risk in patients undergoing liver transplantation.
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